Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OTC Ads’ Vioxx Comparisons Communicate “Options,” Pitts Says

This article was originally published in The Tan Sheet

Executive Summary

OTC analgesic ads comparing the pain relievers to Vioxx (rofecoxib) do not cross the boundary of propriety, according to Peter Pitts, senior VP-health affairs at the public relations firm Manning, Selvage & Lee (New York)

You may also be interested in...



Pfizer Ad Says OTCs “Aren’t As Safe As You Might Think”

A new website from Pfizer touting the firm's COX-2 pain reliever Celebrex (celecoxib) questions the perceived safety profile of over-the-counter drugs

Wyeth, McNeil Strike Swiftly With Ads After Vioxx Recall

Wyeth Consumer Health and McNeil are capitalizing on concerns generated by Merck's recall of its prescription pain reliever Vioxx with ads for Advil (ibuprofen) and Tylenol (acetaminophen)

Reversal Of Fortune? Vioxx Recall Presents Opportunity For NSAID Makers

OTC NSAID manufacturers could be the indirect beneficiaries of Merck's decision to initiate a worldwide recall of its COX-2 inhibitor Vioxx (rofecoxib)

Topics

UsernamePublicRestriction

Register

LL009864

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel